CCMH
NBIX icon

Cornerstone Capital Management Holdings’s Neurocrine Biosciences NBIX Stock Holding History

Cornerstone Capital Management Holdings’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-11,724
Closed -$464K – 1455
2016
Q1 		$464K Sell
11,724
-2,100
-15% -$83.3K ﹤0.01% 1053
2015
Q4 		$782K Buy
13,824
+424
+3% +$21.6K 0.01% 949
2015
Q3 		$534K Sell
13,400
-2,400
-15% -$116K 0.01% 996
2015
Q2 		$755K Buy
15,800
+5,200
+49% +$220K 0.01% 924
2015
Q1 		$421K Buy
10,600
+4,200
+66% +$150K ﹤0.01% 1058
2014
Q4 		$143K Buy
6,400
+3,400
+113% +$64.4K ﹤0.01% 1127
2014
Q3 		$47K Buy
+3,000
New +$44.8K ﹤0.01% 1220

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Cornerstone Capital Management Holdings's NBIX Position: Q2 2016 in Review

Cornerstone Capital Management Holdings sold out of Neurocrine Biosciences (NBIX) in Q2 2016, closing a stake of 11,724 shares — an estimated $464K sold.

Cornerstone Capital Management Holdings first reported a position in NBIX in Q3 2014 and held it in 7 quarters. The position peaked at $782K in Q4 2015. 231 funds tracked by Wall St. Rank hold NBIX as of Q2 2016.

  • Cornerstone Capital Management Holdings reported no remaining Neurocrine Biosciences position as of Q2 2016 after selling out during the quarter.
  • Cornerstone Capital Management Holdings sold 11,724 Neurocrine Biosciences shares in Q2 2016, an estimated $464K.
  • Cornerstone Capital Management Holdings first reported a position in Neurocrine Biosciences in Q3 2014 and held it in 7 quarters.
  • Cornerstone Capital Management Holdings's Neurocrine Biosciences position peaked at $782K in Q4 2015.
  • 231 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2016.

Based on Cornerstone Capital Management Holdings's 13F filing for Q2 2016, filed 12 Aug 2016.